Strong Sales, Deals Propel China Biotechs To 2023 Profitability
Some Move Into Black For First Time
Executive Summary
Strong sales growth and licensing activity in 2023 helped multiple Chinese biotechs to a solid profit performance, some moving into the black for the first time.